Oncology Therapeutics and Drug Development

The Oncology Therapeutics and Drug Development is a peer-reviewed, open-access journal committed to advancing scientific research and innovation in the development of anticancer therapies. The journal serves as an international platform for the publication of high-quality research, breakthrough discoveries, and emerging therapeutic approaches that contribute to improved cancer treatment, drug discovery, and clinical outcomes.

The journal covers a comprehensive range of topics related to oncology therapeutics and drug development, including but not limited to:

Cancer Biology & Molecular Oncology

•  Tumor biology, signaling pathways, oncogenes, tumor suppressors, and microenvironment studies
•  Molecular mechanisms of cancer progression, metastasis, and invasion
•  Biomarker discovery, prognostic indicators, and molecular diagnostics

Targeted Therapies & Precision Oncology

•  Development and evaluation of small molecules, monoclonal antibodies, and peptide-based    therapies
•  Precision medicine approaches, genetic and molecular profiling for individualized treatment
•  Resistance mechanisms and strategies to overcome therapeutic resistance

Immuno-Oncology & Cell-Based Therapies

•  Immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapies (CAR-T, TILs)
•  Tumor-immune interactions, immune modulation, and microenvironment targeting
•  Combination immunotherapies and translational studies

Drug Discovery & Preclinical Development

•  High-throughput screening, lead optimization, and structure-based drug design
•  Pharmacokinetics, pharmacodynamics, and preclinical efficacy evaluation
•  In vitro and in vivo models for cancer therapeutics development

Clinical Trials & Translational Research

•  Early-phase and late-phase clinical trials in oncology
•  Biomarker-driven patient stratification and trial design
•  Safety, efficacy, and outcome measures in therapeutic evaluation

Nanomedicine & Advanced Drug Delivery in Oncology

•  Nanoparticle-based drug carriers, liposomes, and polymeric systems
•  Targeted delivery, controlled release, and tumor-specific therapeutics
•  Toxicity, biocompatibility, and translational nanomedicine studies

Computational Oncology & AI in Drug Development

•  In silico modeling, molecular docking, and drug-target interaction simulations
•  AI/ML-based predictive models for drug efficacy and toxicity
•  Systems biology approaches for personalized therapy design

Emerging Therapies & Translational Innovations

•  Novel therapeutic modalities such as epigenetic drugs, RNA therapeutics, and oncolytic viruses
•  Combination strategies integrating chemotherapy, immunotherapy, and targeted agents
•  Regulatory, ethical, and commercialization considerations in oncology drug development

Cancer Biology & Molecular Mechanisms

•  Oncogenic signaling pathways, tumor suppressor networks, and epigenetic regulation
•  Tumor microenvironment, angiogenesis, hypoxia, and stromal interactions
•  Cancer stem cells, epithelial-to-mesenchymal transition (EMT), and metastasis
•  Molecular biomarkers for diagnosis, prognosis, and therapeutic response

Targeted Therapies & Precision Oncology

•  Small molecule inhibitors, monoclonal antibodies, and receptor-targeted drugs
•  Gene- and pathway-specific therapy development
•  Overcoming drug resistance, tumor heterogeneity, and adaptive therapy strategies
•  Companion diagnostics and precision medicine approaches

Immuno-Oncology & Advanced Cellular Therapies

•  Immune checkpoint blockade (PD-1, PD-L1, CTLA-4) and immune modulation
•  Adoptive cell therapies (CAR-T, TCR, NK cells) and tumor-infiltrating lymphocytes (TILs)
•  Cancer vaccines, cytokine therapies, and combination immunotherapies
•  Tumor-immune microenvironment studies and immunotherapy biomarkers

Drug Discovery, Preclinical & Translational Research

•  High-throughput drug screening, combinatorial therapy testing, and lead optimization
•  Pharmacokinetics, pharmacodynamics, toxicology, and preclinical efficacy evaluation
•  In vitro 3D tumor models, organoids, patient-derived xenografts (PDX)
•  Translational studies bridging lab findings to clinical trials

Clinical Development & Trials in Oncology

•  Phase I–IV clinical trials, trial design, endpoints, and patient stratification
•  Biomarker-driven and adaptive clinical trial methodologies
•  Evaluation of safety, efficacy, and treatment outcomes
•  Regulatory frameworks, ethical considerations, and clinical trial reporting

Nanomedicine & Targeted Drug Delivery Systems

•  Nanoparticle-based therapeutics, liposomes, micelles, and dendrimers
•  Tumor-targeted delivery, controlled release, and pharmacological optimization
•  Theranostics combining diagnostics and therapeutics at the nanoscale
•  Toxicity assessment, biocompatibility, and translational nanomedicine research

Gene & RNA-Based Therapeutics

•  RNA therapeutics, including siRNA, miRNA, mRNA-based treatments
•  CRISPR/Cas gene editing and genome-targeted oncology therapies
•  Viral vectors, oncolytic viruses, and gene-modified cellular therapies
•  Epigenetic modulators and chromatin-targeting drugs

Computational Oncology & Artificial Intelligence Applications

•  Drug-target interaction modeling, molecular docking, and predictive toxicology
•  AI/ML-based identification of drug candidates and personalized therapy prediction
•  Systems biology and network pharmacology in cancer therapy design
•  Big data analytics for patient stratification and clinical outcome prediction

Emerging Therapies & Translational Innovations

•  Combination therapies integrating chemotherapy, targeted therapy, and immunotherapy
•  Novel small molecules, peptides, and biologics for hard-to-treat cancers
•  Organoids, lab-on-chip, and personalized tumor models for therapy testing
•  Policy, regulatory, and ethical considerations in oncology drug development

The journal publishes original research articles, reviews, short communications, case studies, clinical trial reports, and expert perspectives that meaningfully advance the understanding and development of innovative cancer therapeutics.

The Oncology Therapeutics and Drug Development aims to foster collaboration among oncologists, pharmaceutical scientists, researchers, clinicians, industry experts, and policymakers to accelerate the discovery and delivery of effective cancer treatments worldwide. By promoting scientific excellence and knowledge exchange, the journal strives to support the global effort to reduce the burden of cancer through enhanced drug development and therapeutic innovation.